CalciMedica Inc
NASDAQ:CALC
CalciMedica Inc
Research & Development
CalciMedica Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CalciMedica Inc
NASDAQ:CALC
|
Research & Development
-$15.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
CalciMedica Inc
Glance View
CalciMedica, Inc. operates as a biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. The firm is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure.
See Also
What is CalciMedica Inc's Research & Development?
Research & Development
-15.2m
USD
Based on the financial report for Dec 31, 2025, CalciMedica Inc's Research & Development amounts to -15.2m USD.
What is CalciMedica Inc's Research & Development growth rate?
Research & Development CAGR 5Y
6%
Over the last year, the Research & Development growth was -5%. The average annual Research & Development growth rates for CalciMedica Inc have been -3% over the past three years , 6% over the past five years .
